Maximilian Pruss, Mareike Bommert, Sarah Ehmann, Filiz Temizel-Kanbur, Julia Welz, Sabrina Kaiser, Timo Westermann, Edin Karabeg, Kristina Zdanyte, Aleksandra Strojna, Alexander Traut, Florian Heitz, Philipp Harter, Malak Moubarak
{"title":"复发性铂敏感性低级别卵巢癌的细胞减少手术：回顾性单机构经验。","authors":"Maximilian Pruss, Mareike Bommert, Sarah Ehmann, Filiz Temizel-Kanbur, Julia Welz, Sabrina Kaiser, Timo Westermann, Edin Karabeg, Kristina Zdanyte, Aleksandra Strojna, Alexander Traut, Florian Heitz, Philipp Harter, Malak Moubarak","doi":"10.1016/j.ijgc.2025.102672","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Cytoreductive surgery with complete gross resection improves survival in selected patients with recurrent platinum-sensitive epithelial ovarian cancer. Limited data are available on sub-groups with rare histological sub-types undergoing cytoreductive surgery for recurrent disease. We analyzed the outcomes of patients with low-grade histologies undergoing surgery for recurrent disease.</p><p><strong>Methods: </strong>We performed a retrospective exploratory database analysis of patients undergoing cytoreductive surgery for recurrent platinum-sensitive low-grade epithelial ovarian cancer at a tertiary cancer center in Germany between 1999 and 2024.</p><p><strong>Results: </strong>In total, 74 patients were included. The majority had low-grade serous histology (53 of 74 [72%]). Median progression-free survival to first recurrence was 34.1 months. The most common surgical procedures were peritonectomy (72%), lymphadenectomy (34%), and large-bowel resection (30%). The stoma rate was 11%. Complete gross resection was achieved in 51 of 74 patients (69%), and 7 patients (9.5%) had residual disease of 1 to 10 mm. The rate of severe complications (Clavien-Dindo grade ≥3) was 12%. In total, 84% of patients received chemotherapy and 11% received endocrine therapy after surgery. Median progression-free survival and overall survival after cytoreductive surgery for recurrence were 26.5 months and 93 months, respectively. On multi-variate analysis, complete gross resection versus residual disease > 10 mm (p = .002) was the only significant factor for overall survival.</p><p><strong>Conclusions: </strong>Cytoreductive surgery for patients with recurrent platinum-sensitive low-grade ovarian cancer appears feasible and may be associated with clinical benefit. Given the surgical risks and an 11% stoma rate, careful patient selection is essential. Complete gross resection was associated with improved progression-free and overall survival. Additional research is needed to clarify whether a survival benefit exists in cases with residual disease of 1 to 10 mm.</p>","PeriodicalId":14097,"journal":{"name":"International Journal of Gynecological Cancer","volume":"35 12","pages":"102672"},"PeriodicalIF":4.7000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Cytoreductive surgery for recurrent platinum-sensitive low-grade ovarian carcinoma: a retrospective single institution experience.\",\"authors\":\"Maximilian Pruss, Mareike Bommert, Sarah Ehmann, Filiz Temizel-Kanbur, Julia Welz, Sabrina Kaiser, Timo Westermann, Edin Karabeg, Kristina Zdanyte, Aleksandra Strojna, Alexander Traut, Florian Heitz, Philipp Harter, Malak Moubarak\",\"doi\":\"10.1016/j.ijgc.2025.102672\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>Cytoreductive surgery with complete gross resection improves survival in selected patients with recurrent platinum-sensitive epithelial ovarian cancer. Limited data are available on sub-groups with rare histological sub-types undergoing cytoreductive surgery for recurrent disease. We analyzed the outcomes of patients with low-grade histologies undergoing surgery for recurrent disease.</p><p><strong>Methods: </strong>We performed a retrospective exploratory database analysis of patients undergoing cytoreductive surgery for recurrent platinum-sensitive low-grade epithelial ovarian cancer at a tertiary cancer center in Germany between 1999 and 2024.</p><p><strong>Results: </strong>In total, 74 patients were included. The majority had low-grade serous histology (53 of 74 [72%]). Median progression-free survival to first recurrence was 34.1 months. The most common surgical procedures were peritonectomy (72%), lymphadenectomy (34%), and large-bowel resection (30%). The stoma rate was 11%. Complete gross resection was achieved in 51 of 74 patients (69%), and 7 patients (9.5%) had residual disease of 1 to 10 mm. The rate of severe complications (Clavien-Dindo grade ≥3) was 12%. In total, 84% of patients received chemotherapy and 11% received endocrine therapy after surgery. Median progression-free survival and overall survival after cytoreductive surgery for recurrence were 26.5 months and 93 months, respectively. On multi-variate analysis, complete gross resection versus residual disease > 10 mm (p = .002) was the only significant factor for overall survival.</p><p><strong>Conclusions: </strong>Cytoreductive surgery for patients with recurrent platinum-sensitive low-grade ovarian cancer appears feasible and may be associated with clinical benefit. Given the surgical risks and an 11% stoma rate, careful patient selection is essential. Complete gross resection was associated with improved progression-free and overall survival. Additional research is needed to clarify whether a survival benefit exists in cases with residual disease of 1 to 10 mm.</p>\",\"PeriodicalId\":14097,\"journal\":{\"name\":\"International Journal of Gynecological Cancer\",\"volume\":\"35 12\",\"pages\":\"102672\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Gynecological Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijgc.2025.102672\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"OBSTETRICS & GYNECOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Gynecological Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijgc.2025.102672","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
Cytoreductive surgery for recurrent platinum-sensitive low-grade ovarian carcinoma: a retrospective single institution experience.
Objective: Cytoreductive surgery with complete gross resection improves survival in selected patients with recurrent platinum-sensitive epithelial ovarian cancer. Limited data are available on sub-groups with rare histological sub-types undergoing cytoreductive surgery for recurrent disease. We analyzed the outcomes of patients with low-grade histologies undergoing surgery for recurrent disease.
Methods: We performed a retrospective exploratory database analysis of patients undergoing cytoreductive surgery for recurrent platinum-sensitive low-grade epithelial ovarian cancer at a tertiary cancer center in Germany between 1999 and 2024.
Results: In total, 74 patients were included. The majority had low-grade serous histology (53 of 74 [72%]). Median progression-free survival to first recurrence was 34.1 months. The most common surgical procedures were peritonectomy (72%), lymphadenectomy (34%), and large-bowel resection (30%). The stoma rate was 11%. Complete gross resection was achieved in 51 of 74 patients (69%), and 7 patients (9.5%) had residual disease of 1 to 10 mm. The rate of severe complications (Clavien-Dindo grade ≥3) was 12%. In total, 84% of patients received chemotherapy and 11% received endocrine therapy after surgery. Median progression-free survival and overall survival after cytoreductive surgery for recurrence were 26.5 months and 93 months, respectively. On multi-variate analysis, complete gross resection versus residual disease > 10 mm (p = .002) was the only significant factor for overall survival.
Conclusions: Cytoreductive surgery for patients with recurrent platinum-sensitive low-grade ovarian cancer appears feasible and may be associated with clinical benefit. Given the surgical risks and an 11% stoma rate, careful patient selection is essential. Complete gross resection was associated with improved progression-free and overall survival. Additional research is needed to clarify whether a survival benefit exists in cases with residual disease of 1 to 10 mm.
期刊介绍：
The International Journal of Gynecological Cancer, the official journal of the International Gynecologic Cancer Society and the European Society of Gynaecological Oncology, is the primary educational and informational publication for topics relevant to detection, prevention, diagnosis, and treatment of gynecologic malignancies. IJGC emphasizes a multidisciplinary approach, and includes original research, reviews, and video articles. The audience consists of gynecologists, medical oncologists, radiation oncologists, radiologists, pathologists, and research scientists with a special interest in gynecological oncology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
